Abstract
The antipsychotic drug, olanzapine, one of the most widely used drugs in clinical medicine, has a high rate of discontinuation due to inefficacy and/or adverse effects. We identified a single nucleotide polymorphism in the drug metabolizing enzyme, cytochrome P450 3A43 (CYP3A43; rs472660), that highly significantly predicted olanzapine clearance in the Clinical Antipsychotic Trials of Intervention Effectiveness trial (P=5.9e−7). Moreover, at standard antipsychotic doses, 50% of individuals with the high clearance genotype (AA) have trough blood levels below the therapeutic range. Interestingly, a much higher proportion of African Americans carry the A allele compared with Caucasians (allele frequency 67 vs 14%). After accounting for CYP3A43 genotype, race is no longer a significant predictor of olanzapine clearance. Olanzapine clearance was associated with measures of clinical response. Patients with greater clearance had higher symptom ratings and were more likely to discontinue treatment due to an inadequate response. Our data identify a genetic mechanism for variation in olanzapine response and demonstrate that blood level monitoring of olanzapine treatment is advisable.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353: 1209–1223.
Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157–165.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15–31.
Aravagiri M, Marder SR . Determination of olanzapine in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. AAPS PharmSci 2002; 4 Abstract W5016.
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570–584.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM . Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177–193.
Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA . In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996; 41: 181–186.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Consortium TIH . The international HapMap project. Nature 2003; 426: 789–796.
Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol 2011; advance online publication, January 2011; PMID: 21209243 (in press).
Evans WE, Relling MV . Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491.
Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11: 111–121.
Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG . cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386–392.
Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281: 1349–1355.
Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Rienzo A . Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2005; 6: 105–114.
Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755–761.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE et al. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 2008; 3: e2337.
Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66: 465–474.
Davis J, Chen N . Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192–208.
Gardner D, Murphy A, O’Donnell H, Centorrino F, Baldessarini R . International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686–693.
Mauri MC, Steinhilber CPC, Marino R, Invernizzi E, Fiorentini A, Cerveri G et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20: 55–60.
Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR . Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359–388.
Acknowledgements
This research was supported (in part) by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health. The principal investigators of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial were Jeffrey A Lieberman, MD, T Scott Stroup, MD, MPH and Joseph P McEvoy, MD. The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company. We thank Alette Wessels for sharing the ziprasidone population pharmacokinetic model.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Bigos, K., Bies, R., Pollock, B. et al. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 16, 620–625 (2011). https://doi.org/10.1038/mp.2011.38
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2011.38
Keywords
This article is cited by
-
Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features
Molecular Psychiatry (2024)
-
The Impact of Smoking, Sex, Infection, and Comedication Administration on Oral Olanzapine: A Population Pharmacokinetic Model in Chinese Psychiatric Patients
European Journal of Drug Metabolism and Pharmacokinetics (2021)
-
Genetic variation in CYP3A43 is associated with response to antipsychotic medication
Journal of Neural Transmission (2015)
-
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD
Clinical Pharmacokinetics (2015)
-
Identification of Candidate Single-Nucleotide Polymorphisms in NRXN1 Related to Antipsychotic Treatment Response in Patients with Schizophrenia
Neuropsychopharmacology (2014)